← All trials
NCT05829629
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Nov 30, 2024
- First posted
- Apr 26, 2023
- Last posted
- Sep 14, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BlueSky Immunotherapies GmbHLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.